Neonc Technologies Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $121.3M
- Price
- $4.67
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.52%
- Volume
- 167.7K
About
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
Quick stats
Shares outstanding25.9M
Computed float10.5M
Float / shares40.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001979414
Websitehttps://www.neonctech.com
AI Summary
AI-generated1/41
minorbullishinsider transaction
NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t
NeOnc Technologies CEO Amir Heshmatpour purchased 15,000 shares on the open market between August 14 and August 17 at a weighted average price of $3.91, totaling approximately $58,600.
The buying follows positive Phase 2a data for NEO100 in recurrent IDH1-mutant high-grade glioma, which reported a 48.9% six-month progression-free survival rate versus a 20% historical benchmark with a p-value of 0.0047.
NeOnc intends to seek a Type B FDA meeting to discuss a potential registrational pathway, and the company also noted that its second asset, NEO212, has established a recommended Phase 2 dose of 610 mg.
Red flags
- Article is a paid editorial communication ('24/7 is compensated by NTHI')
- Phase 2a study is open-label with small sample size compared to historical benchmark